# Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

> **NCT01972347** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Melanoma Institute Australia** · enrollment: 35 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT01972347
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-10-01
- **Primary completion:** 2017-05-04
- **Final completion:** 2026-05-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972347, "Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01972347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*